Huadong Medicine announced that Hangzhou Sino-US Huadong Pharmaceutical Co., Ltd. (hereinafter referred to as "Sino-US Huadong"), a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (hereinafter referred to as "the Company"), received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration (NMPA). The marketing authorization application for Rilonacept for Injection (trade name: Yanduo®/ARCALYST®) submitted by Sino-US Huadong for the treatment of recurrent pericarditis (RP) was approved.